A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

Exclusion Criteria

• •1. Participant has contraindication(s), warning(s), and/or precaution(s) applicable to vaccination with TDV as specified in the Investigator's Brochure and/or approved product label (as applicable) in the participating country.
• •2. Participant has a known hypersensitivity or allergy to any of the TDV or placebo components (including excipients).
• •3. Participant has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, could interfere with the participant's ability to take part in the trial.
• •4. Participant has a history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (example, Guillain-Barré syndrome).
• •5. Participant has an illness, or history of any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participant due to involvement in this trial.
• •6. Participant has a known or suspected altered immunocompetence, including:
• •1. Chronic administration of oral and/or parenteral steroids at doses considered sufficiently immunosuppressive (example, greater than or equal to \[\>=\] 2 milligram per kilogram \[mg/kg\] body weight prednisone \[or equivalent\] for \>=14 consecutive days, or \>=20 milligram per day \[mg/day\] prednisone \[or equivalent\] administered for \>=14 consecutive days) within 60 days prior to Day 1 (month \[M0\]) (note: use of corticosteroids by inhaled, intranasal, intra-articular, bursal, tendon injection, or topical routes is allowed).
• •2. Receipt of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.
• •3. Receipt of immunostimulants within 60 days prior to Day 1 (M0).
• •4. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).
• •5. Human Immunodeficiency Virus (HIV) infection or HIV-related disease.
• •6. Hepatitis B virus infection.
• •7. Hepatitis C virus infection.
• •8. Genetic immunodeficiency.
• •7. Participant has known or suspected abnormalities of splenic or thymic function.
• •8. Participant has a known bleeding diathesis, or any condition/medication that may be associated with a prolonged bleeding time.
• •9. Participant has a serious chronic or progressive disease deemed to be preclusive to trial entry, that is, not medically stable according to the judgment of the investigator.
• •10. Participant has previously received a vaccination against dengue virus (investigational or licensed).
• •11. Participant had a clinically significant active infection (as assessed by the investigator) or body temperature \>38.0 degree Celsius (\>100.4 degree Fahrenheit) within 3 days of intended TDV or placebo administration.
• •12. Participant has used antipyretics and/or analgesic medications within 24 hours prior to vaccination. The reason for their use (prophylaxis vs treatment) must be documented. Trial entry must be delayed to allow for a full 24 hours to have passed since the last use of antipyretics and/or analgesic medications.
• •13. Participant has a history of substance or alcohol abuse within the past 2 years.
• •14. Female participants who are pregnant (that is, a positive or indeterminate pregnancy test).
• •15. Female participants who are breastfeeding.
• •16. Female participants of childbearing potential who are sexually active and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (M0).
• •17. Female participants of childbearing potential who are sexually active and who refuse to use an acceptable contraceptive method up to 6 weeks post final vaccination on Day 90 (M3). In addition, they must also be advised not to donate ova during this period.
• •18. Participant has received any of the following:
• •1. A licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to TDV or placebo administration on Day 1 (M0). This includes co-administration with routine vaccines.
• •2. A coronavirus vaccine within 14 days prior to TDV or placebo administration.
• •3. A vaccine authorized for emergency use within 28 days prior to TDV or placebo administration.
• •19. Participant is scheduled to receive any other vaccine within 28 days after TDV or placebo administration.
• •20. Participant is participating in any clinical trial with another investigational product 30 days prior to Day 1 (M0) or intending to participate in another clinical trial at any time during the conduct of this trial.
• •21. Participant has taken part in any clinical trial of a dengue or other flavivirus (example, West Nile virus) candidate vaccine, except if it is known that the participant received placebo in those trials.
• •22. Participant or their first-degree relatives are involved in the trial conduct.
• •23. Participant identified as an employee of the investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial center.